A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
Recruiting · NCT07641426 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). | Antibody Mediated Rejection | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07641426 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CASI Pharmaceuticals (China) Co., Ltd. | 1 |
| CASI pharmaceuticals, Inc. | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Friendship Hospital | Beijing | China | 4 |
| The First Affiliated Hospital of Medical College of Xi'an Jiaotong University | Xi'an | China | 1 |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | China | 18 |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 20 |